Political engagement: a key pillar in revitalisation of polio and routine immunisation programmes in the Democratic Republic of the Congo.


Journal

BMJ global health
ISSN: 2059-7908
Titre abrégé: BMJ Glob Health
Pays: England
ID NLM: 101685275

Informations de publication

Date de publication:
22 Oct 2024
Historique:
received: 18 03 2024
accepted: 19 09 2024
medline: 23 10 2024
pubmed: 23 10 2024
entrez: 22 10 2024
Statut: epublish

Résumé

Immunisation is a high priority for improving health outcomes. Yet, in many low-income and middle-income countries, achieving coverage targets independently is hindered by lack of domestic resources and reliance on partners' support. Both the 2001 Abuja Declaration and 2016 Addis Declaration were key political commitments to improving immunisation coverage; however, many signatories have yet to meet international targets. Despite signing the Global Vaccine Action Plan and Addis Declaration, the Democratic Republic of the Congo (DRC) was unable to fully disburse its portion of allocated funds to cover vaccines without support from Gavi, the Vaccine Alliance and the World Bank between 2017 and 2019. Additionally, during the same time, vaccine coverage outcomes indicated negative trends, with over 750 000 children considered 'zero-dose' in 2018. In 2019, a primary focus of the then newly elected President's agenda was universal healthcare. In collaboration with development partners and stakeholders, the first Presidential Forum was held as a public commitment to increasing childhood immunisation and ensuring the country remains polio-free. This article seeks to highlight the key outcomes of the Forum such as the signing of the Kinshasa Declaration, which formally set targets and specified national, provincial and community-level commitments to vaccination and polio eradication. As of 2023, three Forums have been conducted to reiterate political commitment to routine immunisation in the DRC. This type of high-level commitment could serve as a template for other countries struggling to have high engagement as targets for polio eradication and strengthened routine immunisation are set for 2025-2030.

Identifiants

pubmed: 39438072
pii: bmjgh-2024-015675
doi: 10.1136/bmjgh-2024-015675
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Roger Kamba (R)

Ministry of Health, Democratic Republic of the Congo, Kinshasa, Congo (the Democratic Republic of the).

Amine El Mourid (A)

Bill & Melinda Gates Foundation, Seattle, Washington, USA.

Raoul Mpoyi Ngambwa (R)

McKing Consulting, Kinshasa, Congo (the Democratic Republic of the).

Donat Chungu Salumu (D)

Expanded Programme for Immunization, Ministry of Health, Democratic Republic of the Congo, Kinshasa, Congo (the Democratic Republic of the).

Jean-Bernard Le Gargasson (JB)

GAVI the Vaccine Alliance, Geneva, Switzerland.

Daniel Nacoulma (D)

UNICEF, New York, New York, USA.

Marcellin Nimpa Mengouo (M)

World Health Organization, Geneva, Switzerland.

Nolan Meyer (N)

PATH, Democratic Republic of the Congo, Kinshasa, Congo (the Democratic Republic of the).

Christophe Luhata (C)

Expanded Programme for Immunization, Ministry of Health, Democratic Republic of the Congo, Kinshasa, Congo (the Democratic Republic of the).

Nicole A Hoff (NA)

Epidemiology, University of California Los Angeles Jonathan and Karin Fielding School of Public Health, Los Angeles, California, USA nhoff84@ucla.edu.

Hadia Samaha (H)

World Bank, Washington, District of Columbia, USA.

Collard Madika (C)

McKing Consulting, Kinshasa, Congo (the Democratic Republic of the).

Christelle Mputu (C)

Development Catalyst, Kinshasa, Democratic Republic of Congo.

Sylvia Tangney (S)

Epidemiology, University of California Los Angeles Jonathan and Karin Fielding School of Public Health, Los Angeles, California, USA.

Cyril Nogier (C)

GAVI the Vaccine Alliance, Geneva, Switzerland.

Chris Diomi (C)

Ministry of Finance, Democratic Republic of the Congo, Kinshasa, Congo (the Democratic Republic of the).

Sydney Merritt (S)

Epidemiology, University of California Los Angeles Jonathan and Karin Fielding School of Public Health, Los Angeles, California, USA.

Emma Din (E)

USAID, Washington, District of Columbia, USA.

Polydor Kabila (P)

Conseil National de la Courverture Sante Universelle, Ministry of Health, Democratic Republic of the Congo, Kinshasa, Congo (the Democratic Republic of the).

Annabelle Burgett (A)

Bill & Melinda Gates Foundation, Seattle, Washington, USA.

Didier Nyombo (D)

McKing Consulting, Kinshasa, Congo (the Democratic Republic of the).

Emmanuelle Assy (E)

UNICEF, New York, New York, USA.

Dalau Mukadi Nkamba (DM)

Kinshasa School of Public Health, Universite de Kinshasa, Kinshasa, Congo (the Democratic Republic of the).

Lora Bertin (L)

Expanded Programme for Immunization, Ministry of Health, Democratic Republic of the Congo, Kinshasa, Congo (the Democratic Republic of the).

Trad Hatton (T)

PATH, Democratic Republic of the Congo, Kinshasa, Congo (the Democratic Republic of the).

Didine Kaba (D)

Kinshasa School of Public Health, Universite de Kinshasa, Kinshasa, Congo (the Democratic Republic of the).

Anne W Rimoin (AW)

Epidemiology, University of California Los Angeles Jonathan and Karin Fielding School of Public Health, Los Angeles, California, USA.

Elisabeth Mukamba Musenga (E)

Expanded Programme for Immunization, Ministry of Health, Democratic Republic of the Congo, Kinshasa, Congo (the Democratic Republic of the).

Aimé Cikomola (A)

Expanded Programme for Immunization, Ministry of Health, Democratic Republic of the Congo, Kinshasa, Congo (the Democratic Republic of the).

Guillaume Ngoie Mwamba (GN)

VillageReach, Seattle, Washington, USA.

Sylvain Yuman Ramazani (SY)

Ministry of Health, Democratic Republic of the Congo, Kinshasa, Congo (the Democratic Republic of the).

Kamel Senouci (K)

University of Geneva, Geneve, Switzerland.

Magdalena Robert (M)

Bill & Melinda Gates Foundation, Seattle, Washington, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH